Post by babaoriley on Aug 14, 2014 14:23:22 GMT -5
Finally, something makes sense in terms of the share price:
A spokesman for Pfizer today announced that Pfizer would be reintroducing Exubera, with a new and larger inhaler. "We felt that the old inhaler, which many derisively monikered a bong, was the real problem with our marketing efforts. We redesigned the inhaler, it's a bit larger now, but includes am/fm radio, a wi-fi hot spot, two USB ports, a small, but watchable screen, and a prepaid, one-year subscription to Netflix," said the executive VP in charge of world wide sales and other stuff.
The Pfizer EVP continued, "we believe that no other inhaler can touch our new model, and it comes with a convenient case, which can fit, albeit snugly, into an overhead bin on an airplane, making it so convenient and ideal for travel. We see an opportunity to cash in here created by our friends at MannKind and Sanofi, they will advertise their new drug and inhaler, and then people will compare and, well, we expect it to be no contest. The MannKind developed inhaler, nicknamed the Dreamboat, which we call the 'Andrea Doria' at Pfizer, has none of our convenient features, and, further will rip holes in your pockets. Also, we have sworn testimony from Mattel and Hasbro that that little sucker can cause choking if swallowed." The spokesman summed it up, relative to the insulin, "we feel our insulin works just as well as Afrezza, it's all insulin, right? We haven't had a chance to test it head to head yet, but we plan to do that sometime after lunch, er, launch."
A spokesman for Pfizer today announced that Pfizer would be reintroducing Exubera, with a new and larger inhaler. "We felt that the old inhaler, which many derisively monikered a bong, was the real problem with our marketing efforts. We redesigned the inhaler, it's a bit larger now, but includes am/fm radio, a wi-fi hot spot, two USB ports, a small, but watchable screen, and a prepaid, one-year subscription to Netflix," said the executive VP in charge of world wide sales and other stuff.
The Pfizer EVP continued, "we believe that no other inhaler can touch our new model, and it comes with a convenient case, which can fit, albeit snugly, into an overhead bin on an airplane, making it so convenient and ideal for travel. We see an opportunity to cash in here created by our friends at MannKind and Sanofi, they will advertise their new drug and inhaler, and then people will compare and, well, we expect it to be no contest. The MannKind developed inhaler, nicknamed the Dreamboat, which we call the 'Andrea Doria' at Pfizer, has none of our convenient features, and, further will rip holes in your pockets. Also, we have sworn testimony from Mattel and Hasbro that that little sucker can cause choking if swallowed." The spokesman summed it up, relative to the insulin, "we feel our insulin works just as well as Afrezza, it's all insulin, right? We haven't had a chance to test it head to head yet, but we plan to do that sometime after lunch, er, launch."
